Glibornuride (trade name Glutril) is an approved orally bioavailable anti-diabetic drug in Switzerland that belongs to the group of sulfonylureas. It acts as a novel and potent blocker of adenosine 5'-triphosphate (ATP)-sensitive K+ channels (KATP channels) with antihyperglycemic activity. Glibornuride is an . It has been shown to antagonize the relaxant response to the K+ channel opener cromakalim and produce airway smooth muscle relaxation. It is associated with lactic acidosis and hypoglycemia in patients with type 2 diabetes melitus.

纯度：≥98%

CAS：26944-48-9